Prenetics Global (NASDAQ:PRE) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS

Prenetics Global (NASDAQ:PRE) announced its quarterly earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.22, Zacks reports. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%.The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $36.15 million.

Here are the key takeaways from Prenetics Global’s conference call:

• IM8 drove an explosive 2025, pushing Prenetics to record revenue of $92.4M and reaching a $120M annualized run rate for IM8 within its first year, with IM8 contributing $60.1M for the full year and $27.4M in Q4.
• Management completed strategic divestitures (ACT Genomics, Europa, 35% stake in Insighta) and now reports ~$171.1M in adjusted liquid assets with zero debt, strengthening the balance sheet to support IM8’s global expansion.
• Unit economics are strong—projected blended LTV:CAC of ~3x, a payback period of ~3.4 months, and a shift to quarterly subscriptions has doubled blended AOV to ~$233 and produced an ~80% new-customer subscription rate, improving cash flow and retention.
• Prenetics reaffirmed 2026 guidance of $180M–$200M for IM8 with ~60% gross margin, expects a 2026 adjusted EBITDA loss of ~$16M–$20M while investing in growth, and reiterated a clear path to adjusted EBITDA profitability by Q4 2027.
• External validation and upside potential — Roth Capital and Sidoti initiated buy coverage (12‑month targets $36 and $30) and management plans two new SKUs by Q4 2026 (not included in 2026 guidance), providing potential incremental growth.

Prenetics Global Trading Down 3.8%

Shares of Prenetics Global stock traded down $0.76 during midday trading on Thursday, reaching $19.30. The company had a trading volume of 454,935 shares, compared to its average volume of 268,470. The stock has a fifty day simple moving average of $17.68 and a 200 day simple moving average of $13.88. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $22.86. The company has a market capitalization of $324.82 million, a price-to-earnings ratio of -9.51 and a beta of 0.35.

Institutional Investors Weigh In On Prenetics Global

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN acquired a new position in shares of Prenetics Global during the fourth quarter valued at $47,000. JPMorgan Chase & Co. bought a new stake in Prenetics Global during the 3rd quarter worth about $65,000. Boothbay Fund Management LLC acquired a new position in Prenetics Global during the 4th quarter valued at about $241,000. Jump Financial LLC acquired a new position in Prenetics Global during the 4th quarter valued at about $268,000. Finally, Hudson Bay Capital Management LP bought a new position in shares of Prenetics Global in the 4th quarter valued at about $296,000. Institutional investors own 25.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PRE shares. Cantor Fitzgerald increased their target price on shares of Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, January 22nd. Finally, Roth Mkm started coverage on Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $34.00.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.